Since its initial identification, the Omicron variant of SARS-CoV-2 has reshaped the trajectory of the COVID-19 pandemic. The variant was first reported to the World Health Organization on 24 November 2021 by South Africa’s Network for Genomics Surveillance, with its earliest detection occurring in Botswana.
What followed was a rapid global takeover, as Omicron and its expanding family of subvariants became the dominant form of the virus in circulation worldwide. The variant has demonstrated a pronounced capacity for mutation, leading to the development of several distinct subvariants: BA.1, BA.2, BA.3, BA.4, and BA.5. By October 2022, two additional subvariants derived from BA.5—designated BQ.1 and BQ.1.1—had emerged, adding further complexity to the global health landscape.
One of the defining characteristics of Omicron and its offshoots is their increased transmissibility. The BA.4 and BA.5 subvariants, in particular, have proven to be more infectious than earlier iterations of the virus.
This heightened contagiousness extends even to individuals who have received three doses of a COVID-19 vaccine. Despite this, health authorities emphasize that three vaccine doses continue to offer robust protection against severe disease and hospitalization caused by Omicron and its subvariants. The ongoing evolution of the virus has significant implications for public health strategies worldwide.
The emergence of new subvariants such as BQ.1 and BQ.1.1 underscores the critical need for sustained genomic surveillance and rigorous testing. These tools are essential for tracking the virus’s evolution and informing timely adjustments to public health measures.
Omicron’s rapid spread has allowed it to outcompete other variants, raising concerns about the potential strain on healthcare systems and the risks faced by vulnerable populations. As the virus continues to adapt, it is likely that further subvariants will emerge, potentially altering the epidemiological picture. Vaccination remains a cornerstone of the global response.
The protection provided by three doses against severe outcomes has been a vital component of efforts to mitigate the variant’s impact. Maintaining high vaccination rates and adapting vaccine formulations to address emerging subvariants are seen as necessary steps moving forward.
Health officials stress the importance of continued vigilance. The appearance of BQ.1 and BQ.1.1 serves as a reminder that the pandemic is ongoing. In the coming months, monitoring the evolution of Omicron and the effectiveness of current health strategies will be crucial for protecting public health.
